Oncology-based in vivo CRO Market

Increasing cancer incidences are driving the market growth

Market CAGR for oncology-based in vivo CRO is being driven by the increase in the incidence of cancer. The study of cancer diagnosis, prevention, and therapy is known as oncology. In-vivo refers to within a living organism, and CRO stands for contract research organization. The management of cancer with the aid of contract research organization services is known as oncology-based in-vivo CRO.

Additionally, one of the key factors anticipated accelerating the growth and demand of the oncology-based in-vivo contract research organization (CRO) market is the increase in the prevalence of cancer around the world, a disease for which electrosurgical methods are appropriate. Additionally predicted during the forecast period of 2021 to 2028 is the straightforward availability of government funding for research and the rise in CROs' competence in treating cancer would both contribute to the expansion of the market. Additionally, a boost in the focus on oncogene research and an increase in genetic engineering discoveries are both anticipated to support market expansion.

In-vivo contract research organizations (CRO) based on oncology are expected to see significant growth opportunities within the anticipated window due to the rise in specific cancer treatments, the ease of access to a large percentage of medicines, and the rise in the use of these organizations for developing new cancer diagnoses and treatments. On the other hand, the high cost of clinical trials and strict regulatory approvals can impede the growth of the oncology-based in-vivo contract study organization (CRO) market.

Additionally, the high cost of cancer drugs and their negative side effects are anticipated to restrain the development of the oncology-based in-vivo contract research organization (CRO) market.

As an illustration, the World Health Organization projects that there will be 19.3 million additional instances of cancer worldwide in 2020, contributing to an estimated 10 million deaths. Due to this, businesses are outsourcing basic research tasks in order to boost efficiency and concentrate on important development areas. Thus, result in driving the oncology-based in vivo CRO market revenue.

The Global Oncology-based in vivo CRO Market Industry is projected to experience substantial growth over the coming years. With a valuation of 1.4 USD Billion in 2024, the market is expected to expand to 3.36 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate of 8.28% from 2025 to 2035. Such projections underscore the increasing reliance on in vivo CROs for preclinical research and development in oncology. As the demand for innovative cancer therapies continues to rise, the market is likely to witness significant investments and advancements, further solidifying the role of CROs in the oncology landscape.

Technological advancements in the field of oncology research are propelling the Global Oncology-based in vivo CRO Market Industry forward. Innovations such as CRISPR gene editing, advanced imaging techniques, and personalized medicine are enhancing the efficacy of in vivo studies. These technologies allow for more precise targeting of cancer cells and improved understanding of tumor biology. As a result, pharmaceutical companies increasingly rely on in vivo CROs to conduct complex studies that were previously unattainable. This trend is expected to contribute to the market's growth, with projections indicating a rise to 3.36 USD Billion by 2035, driven by the demand for cutting-edge research methodologies.

The rising incidence of cancer globally serves as a primary driver for the Global Oncology-based in vivo CRO Market Industry. According to the World Health Organization, cancer cases are projected to increase significantly, with an estimated 19.3 million new cases diagnosed in 2020. This trend is expected to continue, leading to a heightened demand for innovative therapies and drug development. Consequently, in vivo CROs play a crucial role in preclinical research, enabling pharmaceutical companies to develop effective treatments. As the market evolves, the Global Oncology-based in vivo CRO Market Industry is anticipated to reach a valuation of 1.4 USD Billion in 2024, reflecting the urgent need for advanced oncology solutions.

Emerging markets are becoming increasingly important in the Global Oncology-based in vivo CRO Market Industry. Countries in Asia-Pacific and Latin America are witnessing a rise in cancer cases, prompting a need for localized research and development efforts. As pharmaceutical companies seek to expand their global footprint, they are turning to CROs that can provide in vivo services tailored to regional needs. This trend is likely to enhance the market's growth trajectory, as these regions offer unique opportunities for collaboration and innovation in oncology research. The anticipated growth in these markets may contribute to the overall expansion of the Global Oncology-based in vivo CRO Market Industry.

The surge in investment directed towards oncology research significantly influences the Global Oncology-based in vivo CRO Market Industry. Venture capital and public funding are increasingly allocated to cancer research initiatives, reflecting the urgency to develop new therapies. For instance, the National Cancer Institute has reported substantial funding increases for cancer research projects. This influx of capital enables in vivo CROs to expand their capabilities and enhance their service offerings. Consequently, the market is expected to grow robustly, with estimates suggesting a valuation of 1.4 USD Billion in 2024, driven by the escalating demand for comprehensive oncology research services.

Regulatory bodies worldwide are increasingly supporting the development of oncology drugs, which positively impacts the Global Oncology-based in vivo CRO Market Industry. Initiatives aimed at expediting the approval process for cancer therapies, such as the FDA's Breakthrough Therapy Designation, encourage pharmaceutical companies to invest in research and development. This regulatory environment fosters collaboration between CROs and drug developers, facilitating the efficient execution of in vivo studies. As a result, the market is poised for growth, with a projected compound annual growth rate of 8.28% from 2025 to 2035, reflecting the increasing reliance on CROs for regulatory-compliant research.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American oncology-based in vivo CRO market area will dominate this market. This can be ascribed to the high level of technological development among the CROs in this area. A federal organization called the National Institutes of Health (NIH) provides funding and grants to assist research initiatives. The highest per-capita healthcare spending is in the United States.

Further, the major countries studied in the market report are the US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

Figure 2:  ONCOLOGY-BASED IN VIVO CRO MARKET SHARE BY REGION 2022 (USD Billion)

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Europe oncology-based in vivo CRO market takes second place in terms of market share due to the rise in R&D efforts and the requirement to cut back on overall trial expenses. Further, the German oncology-based in vivo CRO market held a dominant market share, and the UK oncology-based in vivo CRO market was the European region's fastest-growing market.

The Asia-Pacific Oncology-based in vivo CRO Market is anticipated to see the fastest CAGR between 2025 and 2034. This is due to untapped potential, a large patient base, economic growth, and a healthcare system that is constantly improving. Moreover, China’s oncology-based in vivo CRO market held a dominant market share, and the Indian oncology-based in vivo CRO market was the Asia-Pacific region's fastest-growing market.

Leading market players are putting a lot of money on R&D to increase the number of products they offer, which will fuel the growth of the oncology-based in vivo CRO industry. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other businesses. To grow and endure in an increasingly competitive and challenging market environment, oncology-based in vivo CRO industry must provide reasonably priced goods.

One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the oncology-based in vivo CRO industry to develop market sector and provide benefits to customers. In recent years, the oncology-based in vivo CRO industry has provided some of the most important benefits for medicine. Major players in the oncology-based in vivo CRO market, including Biosciences, Charles River Laboratory (CRL), Covance, Crown Bioscience, Eurofins Scientific, ICON Plc, Taconic, and others, invest in operations for research and development in an effort to improve market demand.

Charles River Laboratories International, Inc. is a pharmaceutical firm based in the United States that offers a range of clinical and preclinical laboratory, gene therapy, and cell therapy services to the pharmaceutical, medical device, and biotechnology sectors. Additionally, it provides assistance with basic research, drug discovery, safety and efficacy, clinical support, production, and a range of biomedical products, outsourcing services, and animal research and development (for example, contract research organization services). Approximately 85% of unique FDA-approved medications in 2021, according to the business, were developed with support from them.

In 2019, The company announced that it would pay EUR 448 million (USD 500 million) in cash to acquire Citoxlab, together with the previous purchases of the French firm AccelLAB, Atlanbio, and Solvo Biotechnology.

Labcorp Drug Development is an agreement-based research organization (CRO) that offers nonclinical, preclinical, clinical, and commercialization services to the pharmaceutical and biotechnology sectors. The organization was once known as Covance and is a part of Labcorp, which has over 70,000 employees ly. The world's largest central laboratory network, according to Labcorp Drug Development, is available. Animal rights activists, such as Jane Goodall, have fought Labcorp Drug Development vehemently over their use of animals in testing. In 2019, Covance and Envigo came to an agreement for Covance to purchase the nonclinical research services division of Envigo.

Envigo acquired the research products division of Covance.